In summary, the availability of the thrombolytic agents recombinant tissue plasminogen activator and streptokinase for use in the early treatment of AMI is an important step in the management of a common, often debilitating, and potentially lethal disorder. However, more extensive and complete myocardial salvage than that which can be achieved by reperfusion alone is possible. Clinical trials combining thrombolytic and adjunctive pharmacologic agents offer hope for further advances in the treatment of acute myocardial infarction.
ASJC Scopus subject areas
- Internal Medicine